{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:17:32Z","timestamp":1791983852845,"version":"4.4.0"},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2015,5,14]],"date-time":"2015-05-14T00:00:00Z","timestamp":1431561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0127361","type":"journal-article","created":{"date-parts":[[2015,5,14]],"date-time":"2015-05-14T17:51:05Z","timestamp":1431625865000},"page":"e0127361","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL\/lpr Mouse Model of Systemic Lupus Erythematosus"],"prefix":"10.1371","volume":"10","author":[{"given":"Yuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Shin Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayo","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwen","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Sonderfan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia E.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,5,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nm.2752","article-title":"Taming lupus-a new understanding of pathogenesis is leading to clinical advances","volume":"18","author":"Z Liu","year":"2012","journal-title":"Nat Med"},{"issue":"Suppl 4","key":"ref2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar3917","article-title":"Treatment targets in systemic lupus erythematosus: biology and clinical perspective","volume":"14","author":"V Marian","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 4","key":"ref3","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/ar3919","article-title":"Unmet medical needs in systemic lupus erythematosus","volume":"14","author":"A Lateef","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"437282","DOI":"10.1155\/2012\/437282","article-title":"Systemic lupus erythematosus","volume":"2012","author":"C Putterman","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0140-6736(07)60279-7","article-title":"Systemic lupus erythematosus","volume":"369","author":"DP D'Cruz","year":"2007","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jaci.2010.12.1087","article-title":"Current and novel therapeutics in the treatment of systemic lupus erythematosus","volume":"127","author":"C Yildirim-Toruner","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrm2918","article-title":"HSP90 at the hub of protein homeostasis: emerging mechanistic insights","volume":"11","author":"M Taipale","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.2174\/156652412803306710","article-title":"New paradigm for intrinsic function of heat shock proteins as endogenous ligands in inflammation and innate immunity","volume":"12","author":"Y Tamura","year":"2012","journal-title":"Curr Mol Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1006\/jaut.2001.0549","article-title":"Elevated levels of the 90 kDa heat shock protein (hsp90) in SLE correlate with levels of IL-6 and autoantibodies to hsp90","volume":"17","author":"BJ Ripley","year":"2001","journal-title":"J Autoimmun"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1365-2249.2002.01887.x","article-title":"Lupus-specific kidney deposits of HSP90 are associated with altered IgG idiotypic interactions of anti-HSP90 autoantibodies","volume":"129","author":"A Kenderov","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1471-4159.2006.04221.x","article-title":"The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis","volume":"99","author":"C Dello Russo","year":"2006","journal-title":"J Neurochem"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1002\/art.24047","article-title":"Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis","volume":"58","author":"JW Rice","year":"2008","journal-title":"Arthritis Rheum"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/cmi.2012.5","article-title":"Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL\/lpr mouse model of systemic lupus erythematosus","volume":"9","author":"SK Shimp 3rd","year":"2012","journal-title":"Cell Mol Immunol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc1716","article-title":"HSP90 and the chaperoning of cancer","volume":"5","author":"L Whitesell","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2887","article-title":"Targeting the dynamic HSP90 complex in cancer","volume":"10","author":"J Trepel","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1078-0432.CCR-11-1000","article-title":"Hsp90 molecular chaperone inhibitors: are we there yet?","volume":"18","author":"L Neckers","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1158\/0008-5472.CAN-13-3263","article-title":"Ganetespib and HSP90: translating preclinical hypotheses into clinical promise","volume":"74","author":"DA Proia","year":"2014","journal-title":"Cancer Res"},{"key":"ref18","first-page":"Unit 5","article-title":"Animal models of systemic lupus erythematosus (SLE) and ex vivo assay design for drug discovery","volume":"Chapter 5","author":"MM Seavey","year":"2011","journal-title":"Curr Protoc Pharmacol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.4049\/jimmunol.0902595","article-title":"Identification of new pathogenic players in lupus: autoantibody-secreting cells are present in nephritic kidneys of (NZBxNZW)F1 mice","volume":"184","author":"S Lacotte","year":"2010","journal-title":"J Immunol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2174\/1568009033481787","article-title":"The stress response: implications for the clinical development of hsp90 inhibitors","volume":"3","author":"L Whitesell","year":"2003","journal-title":"Curr Cancer Drug Targets"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1124\/jpet.108.142711","article-title":"Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice","volume":"328","author":"O Kulkarni","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"271694","DOI":"10.1155\/2011\/271694","article-title":"Murine models of systemic lupus erythematosus","volume":"2011","author":"D Perry","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1073\/pnas.90.10.4409","article-title":"Mature T cells of autoimmune lpr\/lpr mice have a defect in antigen-stimulated suicide","volume":"90","author":"JH Russell","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.4049\/jimmunol.161.4.1686","article-title":"TCR ligation on CD8+ T cells creates double-negative cells in vivo","volume":"161","author":"WZ Mehal","year":"1998","journal-title":"J Immunol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/ar3251","article-title":"Abnormalities of T cell signaling in systemic lupus erythematosus","volume":"13","author":"VR Moulton","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"LA Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1172\/JCI73411","article-title":"CaMK4-dependent activation of AKT\/mTOR and CREM-alpha underlies autoimmunity-associated Th17 imbalance","volume":"124","author":"T Koga","year":"2014","journal-title":"J Clin Invest"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1002\/art.22119","article-title":"Abrogation of skin disease in LUPUS-prone MRL\/FASlpr mice by means of a novel tylophorine analog","volume":"54","author":"JY Choi","year":"2006","journal-title":"Arthritis Rheum"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nri749","article-title":"Roles of heat-shock proteins in innate and adaptive immunity","volume":"2","author":"P Srivastava","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1096\/fj.06-7637com","article-title":"Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis","volume":"21","author":"V Poulaki","year":"2007","journal-title":"FASEB J"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"563","DOI":"10.4049\/jimmunol.1000222","article-title":"EC144, a synthetic inhibitor of heat shock protein 90, blocks innate and adaptive immune responses in models of inflammation and autoimmunity","volume":"186","author":"TJ Yun","year":"2011","journal-title":"J Immunol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2012.10.008","article-title":"The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE","volume":"255","author":"L Lisi","year":"2013","journal-title":"J Neuroimmunol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/ard.52.6.436","article-title":"Differential heat shock protein overexpression and its clinical relevance in systemic lupus erythematosus","volume":"52","author":"VB Dhillon","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0896-8411(89)90154-6","article-title":"Elevated levels of the 90 kd heat shock protein in a proportion of SLE patients with active disease","volume":"2","author":"PM Norton","year":"1989","journal-title":"J Autoimmun"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/rheumatology\/33.10.923","article-title":"Detection of autoantibodies to the 90 kDa heat shock protein in systemic lupus erythematosus and other autoimmune diseases","volume":"33","author":"SE Conroy","year":"1994","journal-title":"Br J Rheumatol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0049-0172(98)80032-2","article-title":"The regulation of heat shock proteins and their role in systemic lupus erythematosus","volume":"28","author":"A Stephanou","year":"1998","journal-title":"Semin Arthritis Rheum"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1006\/jaut.1998.0194","article-title":"Elevation of IL-6 in transgenic mice results in increased levels of the 90 kDa heat shock protein (hsp90) and the production of anti-hsp90 antibodies","volume":"11","author":"A Stephanou","year":"1998","journal-title":"J Autoimmun"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/rheumatology\/34.7.610","article-title":"Increased levels of antibodies to heat shock proteins with increasing age in Mrl\/Mp-lpr\/lpr mice","volume":"34","author":"G Faulds","year":"1995","journal-title":"Br J Rheumatol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3892\/ijo.2012.1698","article-title":"Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression","volume":"42","author":"S He","year":"2013","journal-title":"Int J Oncol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10637-014-0095-4","article-title":"The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer","volume":"32","author":"S He","year":"2014","journal-title":"Invest New Drugs"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/1535-7163.MCT-11-0755","article-title":"Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy","volume":"11","author":"W Ying","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/00003495-199142050-00005","article-title":"Cyclophosphamide toxicity. Characterising and avoiding the problem","volume":"42","author":"LH Fraiser","year":"1991","journal-title":"Drugs"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1191\/096120301671376017","article-title":"Cyclophosphamide for the treatment of systemic lupus erythematosus","volume":"10","author":"K Takada","year":"2001","journal-title":"Lupus"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/35100573","article-title":"From T to B and back again: positive feedback in systemic autoimmune disease","volume":"1","author":"MJ Shlomchik","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrrheum.2010.60","article-title":"T cells as therapeutic targets in SLE","volume":"6","author":"JC Crispin","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1379\/1466-1268(2000)005<0052:THSIGS>2.0.CO;2","article-title":"The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation","volume":"5","author":"T Schnaider","year":"2000","journal-title":"Cell Stress Chaperones"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.4049\/jimmunol.1200593","article-title":"Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells","volume":"190","author":"J Bae","year":"2013","journal-title":"J Immunol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1476-9255-11-10","article-title":"Inhibitory effects of heat shock protein 90 blockade on proinflammatory human Th1 and Th17 cell subpopulations","volume":"11","author":"S Tukaj","year":"2014","journal-title":"J Inflamm"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/exd.12476","article-title":"Immunomodulatory effects of heat shock protein 90 inhibition on humoral immune responses","volume":"23","author":"S Tukaj","year":"2014","journal-title":"Exp Dermatol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"347520","DOI":"10.1155\/2013\/347520","article-title":"Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review","volume":"2013","author":"A Oglesby","year":"2013","journal-title":"Int J Rheumatol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1191\/0961203304lu2012oa","article-title":"Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide","volume":"13","author":"GE Katsifis","year":"2004","journal-title":"Lupus"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2407-13-152","article-title":"A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies","volume":"13","author":"JW Goldman","year":"2013","journal-title":"BMC Cancer"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1158\/1078-0432.CCR-12-3381","article-title":"A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer","volume":"19","author":"MA Socinski","year":"2013","journal-title":"Clin Cancer Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0127361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T14:40:06Z","timestamp":1691678406000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0127361"}},"subtitle":[],"editor":[{"given":"Jose","family":"Crispin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,5,14]]},"references-count":53,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,5,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0127361","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,14]]}}}